ResMed shares have declined significantly, with reports of the drop ranging from 20% to 30% this year. The decline has led to speculation about whether the shares are now a buying opportunity. Some outlets suggest the shares may be undervalued, while others note the drop as part of a broader market trend, with the extent of the decline and the company's prospects unclear.